Inhibikase Therapeutics (NASDAQ:IKT) Upgraded by Cantor Fitzgerald to Strong-Buy Rating

Cantor Fitzgerald upgraded shares of Inhibikase Therapeutics (NASDAQ:IKT) to a strong-buy rating in a report released on Thursday morning,Zacks.com reports.

IKT has been the topic of several other reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Inhibikase Therapeutics in a research report on Wednesday, October 8th. Wall Street Zen raised shares of Inhibikase Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, September 20th. Lifesci Capital raised shares of Inhibikase Therapeutics to a “strong-buy” rating in a research report on Monday, December 1st. Finally, Zacks Research raised shares of Inhibikase Therapeutics to a “hold” rating in a research note on Tuesday, December 2nd. Two research analysts have rated the stock with a Strong Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Inhibikase Therapeutics presently has an average rating of “Moderate Buy”.

Inhibikase Therapeutics Trading Up 1.0%

NASDAQ:IKT traded up $0.02 on Thursday, reaching $1.54. The stock had a trading volume of 642,185 shares, compared to its average volume of 403,199. The stock has a market cap of $115.78 million, a P/E ratio of -3.95 and a beta of 0.88. Inhibikase Therapeutics has a 12-month low of $1.33 and a 12-month high of $4.20. The stock’s fifty day simple moving average is $1.55.

Inhibikase Therapeutics (NASDAQ:IKT) last announced its quarterly earnings data on Friday, November 14th. The company reported ($0.13) earnings per share (EPS) for the quarter.

About Inhibikase Therapeutics

Inhibikase Therapeutics, Inc, a clinical stage pharmaceutical company, develops therapeutics for Parkinson’s Disease (PD) and related disorders that arise inside and outside of the brain. The company’s product candidates include IkT-148009, a small molecule Abelson tyrosine kinase inhibitor for use in the treatment of PD, as well as gastrointestinal complications that arise as early symptoms of PD, such as swallowing, dysphagia, neurogenic constipation, and multiple system atrophy; and IkT-001Pro, a prodrug of the anti-cancer agent Imatinib that is in preclinical development to minimize gastrointestinal side effects and for the treatment of blood and stomach cancers.